Manufacturing innovation to drive down cell therapy costs

Minsoo Khang; Smruthi Suryaprakash; Megan Kotrappa; Widya Mulyasasmita; Shana Topp; John Wu

doi:10.1016/j.tibtech.2023.04.006

Manufacturing innovation to drive down cell therapy costs

Trends Biotechnol. 2023 Oct;41(10):1216-1219. doi: 10.1016/j.tibtech.2023.04.006. Epub 2023 May 24.

Authors

Minsoo Khang¹, Smruthi Suryaprakash¹, Megan Kotrappa², Widya Mulyasasmita², Shana Topp³, John Wu⁴

Affiliations

¹ Boston Consulting Group, Boston, MA, USA.
² B Capital Group, San Francisco, CA, USA.
³ Boston Consulting Group, Boston, MA, USA. Electronic address: topp.shana@bcg.com.
⁴ Boston Consulting Group, Boston, MA, USA. Electronic address: wu.john@bcg.com.

PMID: 37236813
DOI: 10.1016/j.tibtech.2023.04.006

Abstract

Chimeric antigen receptor T cells (CAR-T) have demonstrated their potential to revolutionize cancer treatment. However, manufacturing remains a challenge. Multiple manufacturing innovations [e.g., vector and gene engineering, process improvements, hardware innovation, digital innovation, and point-of-care (POC) manufacturing] have the potential to help realize the full potential of CAR-T therapies.

Keywords: CAR-T; autologous; cancer therapy; cell therapy; manufacturing; process development.

MeSH terms

Cell- and Tissue-Based Therapy
Genetic Engineering
Immunotherapy, Adoptive
Receptors, Chimeric Antigen* / genetics

Substances

Receptors, Chimeric Antigen